Navigation Links
Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkin's Lymphoma
Date:5/27/2008

open to both treatment-naive and previously treated patients, ultimately enrolling a much larger treatment-naive population (78%). Patients were randomized at a one-to-one ratio to receive either Specifid or placebo following a standard course of Rituxan. The trial was conducted at 67 centers in the U.S.

Conference Call and Webcast

Favrille's management team will host a conference call today at 8:30 a.m. Eastern Time to discuss the information contained in this press release. A live audio webcast will be available on the Investor Relations section of the Company's web site at http://www.favrille.com . Alternatively, callers may participate in the conference call by dialing (866) 831-6267 or (617) 213-8857, passcode 99549869. A telephone replay of the call will also be available for 48 hours. The telephone replay can be accessed by dialing (888) 286-8010 or (617) 801-6888, passcode 20389415.

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system.

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Favrille's product candidates, proprietary technologies and research and clinical development programs. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Favrille's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to Favrille's ability to continue its operations, conserve cash or recognize value on our assets and additional risks discussed in Favrille's filings with the Securiti
'/>"/>

SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Favrille Reports First Quarter 2008 Financial Results
2. Favrille to Host Conference Call and Live Webcast to Discuss First Quarter 2008 Financial Results on May 8, 2008
3. Favrille Reports Fourth Quarter and Year End 2007 Financial Results
4. Favrille Announces $21.1 Million Registered Direct Offering
5. Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
6. Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007
7. Favrille to Present at BIO InvestorForum
8. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
9. Favrille CEO to Present at Bear Stearns Healthcare Conference
10. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
11. Dragon Pharma Announces June 26, 2008 for 2008 Annual Shareholders Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... The AMA is pleased to share ... Alaska that Alaska Governor Sean Parnell has signed House ... public use of Unmanned Aircraft Systems and the continuation ... 255states that it is, “An Act relating to unmanned ... unmanned aircraft system.” It defines State of Alaska laws ...
(Date:8/22/2014)... Canada (PRWEB) August 22, 2014 ... in model organisms can be accelerated by exome ... and manufacturing technologies, the custom SeqCap EZ Developer ... research. , Mr. Watson will additionally present how ... with commercially available human and mouse exome kits. ...
(Date:8/21/2014)... 21, 2014  BioSpecifics Technologies Corp. (NASDAQ: ... in class collagenase-based products marketed as XIAFLEX ® ... U.S. and XIAPEX ® in the EU, ... randomized, double-blind Phase 2a study of CCH for ... panniculopathy. The results showed that all three doses ...
(Date:8/21/2014)... A Finnish-Swedish research group at the Institute for ... Karolinska institutet, Stockholm, has developed a novel "man ... infection. This innovative diagnostic aid was described in ... August. The method is based on computer vision ... systems combined with visualization of only the diagnostically ...
Breaking Biology Technology:State of Alaska Signs Unmanned Aircraft Systems Bill 2Efficient Identification of Protein-Coding Variants in a Model Organism Through Exome Sequencing, New Webinar Hosted by Xtalks 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5A novel 'man and machine' decision support system makes malaria diagnostics more effective 2
... Forecasts Growth of More Than 40%, NEW ... /Xinhua-PRNewswire-,FirstCall/ -- China Pharma Holdings, Inc. ("China Pharma") ... generic and brand,bio-pharmaceutical products in China, announced today ... to exceed 40%., According to recent sales ...
... Genome,Sciences, Inc. (Nasdaq: HGSI ) announced today that ... be webcast and may be accessed at, http://www.hgsi.com , ... of Human Genome Sciences, senior management team will present,a ... am Eastern,Time., Investors interested in listening to the ...
... physicians credentialed,to practice at the Texas Institute for Surgery ... at its annual Best Doctors event., "Texas Institute ... in the country and it is a tremendous honor ... this prestigious list. The physicians who,operate at TIS are ...
Cached Biology Technology:China Pharma Holdings, Inc. Projects 3rd Quarter 2008 Revenue Growth to Exceed 40% 2Annual List of 'Best Doctors in Dallas' Showcases Texas Institute for Surgery Physicians 2
(Date:8/22/2014)... Thanks to important discoveries in basic and clinical ... has mobilized into a complex offensive spanning multiple ... Alberta chemistry lab could help find new and ... a compound that targets a specific enzyme overexpressed ... in cells from brain tumours. , Chemistry professor ...
(Date:8/22/2014)... antioxidants and can reduce free radical damage. ... oxidative stress? Jianbo Zhao and co-workers from ... University, China discovered that green tea polyphenol ... apoptosis, indicating green tea polyphenols play a ... oxidative stress. The relevant study has been ...
(Date:8/22/2014)... the birds and the bees. But that old ... fertilized. The fertilization process for flowering plants is ... male and female reproductive cells. New research from ... Munich, and including Carnegie,s Wolf Frommer, David Ehrhardt, ... signaling process that guides flowering plant fertilization. It ...
Breaking Biology News(10 mins):New enzyme targets for selective cancer therapies 2New enzyme targets for selective cancer therapies 3Calcium and reproduction go together 2
... and philosophers across the nation are protesting a new ... a letter sent Monday to U.S. Secretary of the ... Public Works, and the House Committee on Natural Resources, ... legal opinion from the Solicitor of the U.S. Department ...
... to a new brain study, even people who seemed resilient but ... toppled on Sept. 11, 2001, have brains that are more reactive ... away. , That is the finding of a new Cornell study ... post-traumatic stress disorder (PTSD) or major depression. One of the first ...
... launched to try to boost the income of the world’s ... provide consumers with more nutritious, better tasting food. , New ... rice varieties that could fetch a higher price from consumers, ... The main aim of the new International Network for Quality ...
Cached Biology News:Legal ruling may put endangered species in danger 2Traumas like Sept. 11 make brains more reactive to fear 2New knowledge improves rice quality 2
This antibody detects cdc42 on SDS-PAGE immunoblots....
Goat polyclonal to DDDDK tag (FITC) ( Abpromise for all tested applications)....
Rabbit polyclonal to TRPM8 (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 79054 SwissProtID: Q3YFM7...
...
Biology Products: